Dicyclomine Does Not Cause Stomach Bleeding
Dicyclomine (Bentyl) is an anticholinergic/antispasmodic medication that does not directly cause upper gastrointestinal bleeding. In fact, the FDA label explicitly lists "unstable cardiovascular status in acute hemorrhage" as a contraindication 1, indicating the drug should be avoided in patients already bleeding—not because it causes bleeding, but because its anticholinergic effects could be problematic in hemodynamically unstable patients.
Mechanism and Safety Profile
Dicyclomine works through two mechanisms 1:
- Anticholinergic effect at acetylcholine receptors (antimuscarinic action)
- Direct smooth muscle relaxation (musculotropic effect)
Neither mechanism promotes mucosal injury or bleeding. Unlike NSAIDs, aspirin, or antiplatelet agents that are well-documented causes of GI bleeding 2, dicyclomine does not:
- Inhibit prostaglandin synthesis
- Impair platelet function
- Damage the gastric mucosal barrier
- Increase gastric acid secretion
Clinical Trial Safety Data
In controlled trials involving over 100 patients receiving dicyclomine 160 mg daily (40 mg four times daily), the reported adverse effects were entirely anticholinergic in nature 1, 3:
- Dry mouth (33%)
- Dizziness (29%)
- Blurred vision (27%)
- Nausea (14%)
Notably absent from this list: any mention of GI bleeding, ulceration, or hemorrhage. The side effect profile remained consistent across multiple studies 3, 4, 5, with no reports of bleeding complications.
Important Clinical Distinction
The evidence provided extensively discusses drugs that do cause GI bleeding:
- NSAIDs increase bleeding risk 2-4 fold, with specific agents like ketorolac showing 20-fold increased risk 6
- Antiplatelet agents (aspirin, clopidogrel) increase bleeding risk 2-3 fold when combined 2
- Anticoagulants combined with NSAIDs increase bleeding risk 3-6 fold 7
These medications require PPI co-therapy in high-risk patients 8, 2. Dicyclomine requires no such gastroprotection because it poses no bleeding risk.
Rare Thrombotic Concern (Not Bleeding)
One case report documented thrombosis following inadvertent intravenous administration of dicyclomine mixed with ketorolac 9. This represents:
- Wrong route of administration (IV instead of intramuscular)
- A thrombotic (clotting) complication, not bleeding
- An isolated case with confounding ketorolac administration
This further confirms dicyclomine does not promote bleeding—if anything, the concern would theoretically be in the opposite direction with IV misadministration.
Clinical Bottom Line
Dicyclomine can be safely prescribed without concern for causing stomach bleeding. If your patient has GI bleeding, look for the actual culprits: NSAIDs, aspirin, antiplatelet agents, anticoagulants, or underlying ulcer disease 10, 11. The anticholinergic side effects of dicyclomine (dry mouth, blurred vision, urinary retention) are the relevant safety concerns—not hemorrhage.